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Bone-conditioned medium contributes to initiation and
progression of osteogenesis by exhibiting synergistic TGF-β1/
BMP-2 activity
Maria B. Asparuhova1, Jordi Caballé-Serrano1,2,3, Daniel Buser2 and Vivianne Chappuis2
Guided bone regeneration (GBR) often utilizes a combination of autologous bone grafts, deproteinized bovine bone mineral
(DBBM), and collagen membranes. DBBM and collagen membranes pre-coated with bone-conditioned medium (BCM) extracted
from locally harvested autologous bone chips have shown great regenerative potential in GBR. However, the underlying molecular
mechanism remains largely unknown. Here, we investigated the composition of BCM and its activity on the osteogenic potential of
mesenchymal stromal cells. We detected a fast and signiﬁcant (P < 0.001) release of transforming growth factor-β1 (TGF-β1) from
autologous bone within 10 min versus a delayed bone morphogenetic protein-2 (BMP-2) release from 40min onwards. BCMs
harvested within short time periods (10, 20, or 40 min), corresponding to the time of a typical surgical procedure, signiﬁcantly
increased the proliferative activity and collagen matrix production of BCM-treated cells. Long-term (1, 3, or 6 days)-extracted BCMs
promoted the later stages of osteoblast differentiation and maturation. Short-term-extracted BCMs, in which TGF-β1 but no BMP-2
was detected, reduced the expression of the late differentiation marker osteocalcin. However, when both growth factors were
present simultaneously in the BCM, no inhibitory effects on osteoblast differentiation were observed, suggesting a synergistic TGF-
β1/BMP-2 activity. Consequently, in cells that were co-stimulated with recombinant TGF-β1 and BMP-2, we showed a signiﬁcant
stimulatory and dose-dependent effect of TGF-β1 on BMP-2-induced osteoblast differentiation due to prolonged BMP signaling and
reduced expression of the BMP-2 antagonist noggin. Altogether, our data provide new insights into the molecular mechanisms
underlying the favorable outcome from GBR procedures using BCM, derived from autologous bone grafts.
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INTRODUCTION
Despite the increasing number of new bone-grafting substitutes,
autografts remain the gold standard for bone augmentation and
reconstruction in oral, maxillofacial and orthopedic surgery due to
their excellent and cost-effective combination of biological and
mechanical properties.1–3 Autologous bone is the only clinically
available bone graft source that contains viable osteogenic
precursor cells (osteogenicity), releases growth factors capable
of inducing new bone formation (osteoinduction), and provides a
scaffold for the ingrowth of new blood vessels and the migration
of osteoprogenitor cells (osteoconduction).4 The combination of
collagen membranes with autologous bone and a superﬁcial layer
of deprotenized bovine bone mineral (DBBM) is a widely used
guided bone regeneration (GBR) technique,5,6 which bears little
risk of recession of the facial mucosa and sustains the long-term
stability of the augmented volume.2,7,8 Graft consolidation
depends on the orchestrated activation of numerous growth
factors in both the host and the graft. However, a precise
characterization of the factors released by bone autografts over
time and their contribution to the bone-forming process remains
lacking.
Recent research from our laboratory aimed to discover the
molecular mechanisms that underlie the favorable long-term
results from bone augmentation procedures using autologous
bone chips in combination with a bone substitute. The harvesting
technique signiﬁcantly inﬂuences the survival of bone cells
contained within the autograft,9 and subsequently alters the
release of osteoinductive growth factors.10 Furthermore, a 24-hour
extraction of untreated bone chips with cell culture medium had
the potential to affect a variety of cell types implicated in graft
consolidation.11,12 This so-called bone-conditioned medium (BCM)
induces osteoclastogenesis in bone marrow cultures13,14, and
improves oral ﬁbroblast cell activity through transforming growth
factor (TGF)-β1 signaling.15–17 Moreover, collagen membranes
rapidly adsorb the TGF-β1 activity contained in BCM, provoking
changes in the gene expression pattern of oral ﬁbroblasts grown
on the membranes.18 Thus, pre-coating DBBM and collagen
membranes with biologically active BCM that is extracted from
locally harvested autologous bone chips during the surgical
procedure has great clinical potential.
In addition to TGF-β, bone formation is regulated by growth
factors such as Bone morphogenic protein (BMP)-2, 4, 5, 6, 7, and
9.19 A short-term expression of BMP-2 is sufﬁcient to irreversibly
induce osteogenesis.20 Thus, the goal of the present study is to
analyze the TGF-β1 and BMP-2 protein release from autologous
bone into BCM that is harvested for short periods (minutes)
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corresponding to the time of a typical surgical procedure, as well
as the protein release after extended periods of time correspond-
ing to the early days after the augmentation procedure occurred.
The study further aimed to investigate the osteogenic response
induced by BCM in the mesenchymal stromal line, ST2, thus
providing insights into the complexity of bone matrix dynamics
and the clinical potential of BCM. We hypothesized that
BCM harvested within minutes might be sufﬁciently potent
to exert a positive effect on the osteogenic properties of
ST2 cells.
RESULTS
Release of TGF-β1 and BMP-2 from cortical bone chips over time
Bone chips extracted for various time periods showed very fast
release kinetics for TGF-β1, compared to BMP-2 (Fig. 1a, b).
Signiﬁcant quantities of TGF-β1 (2.1 ng·mL−1, P < 0.001)
were measured in BCM prepared with Ringer’s solution (RS)
within 10 min (Fig. 1a, BCM-RS). The initial release (within minutes)
of TGF-β1 into BCM prepared with a 1:1 mixture of Ringer’s
solution and autologous serum (RS+S) (Fig. 1a, BCM-RS+S) was
signiﬁcant, but lower than the release into BCM-RS, most likely
due to differences in the osmotic pressure generated by the two
diluents. Whereas, no signiﬁcantly higher quantities of TGF-β1
were detected in BCM-RS at time points longer than 10min, the
yields measured in BCM-RS+S prepared over 1, 3, and 6 d were
over twofold higher (P < 0.001) than the amounts extracted at the
same time points in RS. In contrast to TGF-β1, BMP-2 was not
detected in BCM within 10 and 20min in either of the two diluents
(Fig. 1b). However, signiﬁcant and increasing amounts (between
10 and 55 pg·mL−1, P < 0.001) of this growth factor were released
from bone chips between 1 and 6 days.
BCM induces enhanced phosphorylation of TGF-β1- and BMP-2-
speciﬁc R-Smads in mesenchymal stromal ST2 cells
To investigate whether the quantities of TGF-β1 and BMP-2
released from bone chips within different time periods are
sufﬁcient to activate TGF-β and BMP signaling, respectively, we
analyzed the phosphorylation of TGF-β1- and BMP-2-speciﬁc
receptor-regulated Smad proteins (R-Smads) in BCM-treated ST2
cells (Fig. 1c, d). Smad2 responds to TGF-β1, whereas most BMPs
activate Smad1/5/8 as their R-Smads. Compared to the basal levels
of phospho-Smad2 detected in control RS-treated ST2 cells, the
phosphorylation of Smad2 was signiﬁcantly increased in cells
treated with BCM-RS prepared over 1, 3, and 6 days (Fig. 1c, BCM-
RS). BCM-RS+S appeared to be even more potent, since the
preparation made within 20min was already able to induce
signiﬁcant Smad2 phosphorylation (P < 0.05), compared to the
basal phospho-Smad2 levels in the control cells (Fig. 1c, BCM-RS
+S). Compared to control cells, signiﬁcant phosphorylation of
Smad1/5/8 was observed in cells treated with BCM-RS extracted
from 40min onwards as well as in cells treated with BCM-RS+S
extracted from 20min onwards (Fig. 1d).
BCM harvested within short time periods induces proliferation of
ST2 cells
Osteogenesis involves chemotaxis and proliferation of osteoblast
precursors, differentiation to the mature osteoblast phenotype
with the synthesis of extracellular matrix proteins, and mineraliza-
tion of the resulting matrix. We ﬁrst assessed the proliferative
ability of ST2 cells treated with different BCM preparations (Fig. 2).
Compared to control cells, ST2 cells treated with BCMs extracted
for 10, 20, 40min, or 1 d in each of the two diluents showed a
signiﬁcant increase in 5-bromo-20-deoxyuridine (BrdU) uptake
into newly synthesized DNA until they reached conﬂuence. In
contrast, ST2 cells treated with BCMs extracted over 3 or 6 days
behaved like the control cells. Thus, BCMs harvested for short
periods (up to 1 day) strongly stimulated the proliferation of
osteoprogenitors.
BCM induces osteoblast differentiation of ST2 cells
To assess the osteogenic potential of BCM, we monitored the
expression of genes encoding bone matrix proteins such as
collagen type I (Col1a1 and Col1a2) and osteopontin (also known
as secreted phosphoprotein 1, Spp1), as well as genes encoding
the differentiation markers, runt-related transcription factor 2
(Runx2), osteocalcin (or bone gamma-carboxyglutamate protein 2,
Bglap2), bone sialoprotein (or integrin-binding sialoprotein, Ibsp),
and alkaline phosphatase (Alpl) in BCM-treated ST2 cells.
BCMs made within short (10, 20, or 40 min) and long (1, 3, or
6 d) time periods in each of the two diluents (RS or RS+S) caused a
continuous and signiﬁcant increase in Col1a1, Col1a2, and Spp1
mRNAs above the expression levels detected in control cells
treated with the diluents alone (Fig. 3a–c). This suggests a
continuous accumulation in the BCM of factors released from the
autografts that substantially inﬂuence the early stages of
differentiation, namely, the production of matrix onto which the
mineral is deposited.
Next, Runx2, Bglap2, Ibsp, and Alpl were generally upregu-
lated in cells treated with BCMs extracted over days with a trend
of higher potency exhibited by the BCM-RS+S compared to the
BCM-RS preparations, most likely due to the complex composi-
tion of serum present in the former (Fig. 3d–g). In contrast, all
four differentiation markers showed decreased mRNA levels in
cells treated with BCMs that were extracted for minutes in each
of the two diluents, compared to control cells. The down-
regulation was most signiﬁcant for the late differentiation
markers Bglap2 and Ibsp (Fig. 3e, f), suggesting an inhibitory
effect of BCM extracted for minutes on osteoblast
maturation.
Finally, we assessed the mineral deposition capacity of BCM-
treated ST2 cells (Fig. 3h, i). In agreement with the gene
expression analysis and similar to control cells grown in the
absence of BCM, BCMs made within minutes did not induce any
signiﬁcant matrix mineralization. In contrast, mineral deposition
was strongly and continuously enhanced more than ﬁve-fold (P <
0.001) in cells treated with BCMs extracted over 1, 3, and 6 days.
TGF-β1 exhibits a stimulatory and dose-dependent effect on BMP-
2-induced osteoblast differentiation
As shown above, BCM harvested for minutes induces genes
encoding bone matrix proteins, but does not contribute to matrix
mineralization, whereas BCMs prepared over days contribute to
the progression of osteogenesis. These differential actions
observed for BCMs containing TGF-β1 but no detectable BMP-2
levels versus BCMs containing both proteins simultaneously imply
an intriguing crosstalk between the two growth factors. To study
the combined effect of TGF-β1 and BMP-2 on osteoblast
differentiation, ST2 cells were treated with increasing concentra-
tions of recombinant TGF-β1 in the absence or presence of
recombinant BMP-2 (Fig. 4). Similar to the effect seen in cells
treated with short-term extracted BCMs, increasing concentrations
of TGF-β1 applied in the absence of BMP-2 caused signiﬁcant and
dose-dependent increases of Col1a1, Col1a2, and Spp1 mRNAs
(Fig. 4a), but a slight decrease of Runx2, Bglap2, Ibsp, and Alpl
mRNAs (Fig. 4b), compared to the respective expression levels in
untreated cells. As expected, the application of BMP-2 alone
caused a signiﬁcant upregulation of all osteoblast-speciﬁc
mRNAs above the expression levels seen in untreated cells
(Fig. 4a, b). Furthermore, a dose-dependent induction of all tested
genes was observed when TGF-β1 was applied together with
BMP-2.
Next, we assessed the mineralization capacity of growth factor-
treated ST2 cells (Fig. 4c). As expected, mineralization was
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stimulated by BMP-2 but not TGF-β1. However, when the two
growth factors were applied concomitantly, TGF-β1 signiﬁcantly
(P < 0.05) enhanced the BMP-2-induced deposition of mineralized
matrix by ST2 cells.
Together, these results demonstrate that TGF-β1 exhibits a
stimulatory and dose-dependent effect on the BMP-2-induced
differentiation of ST2 cells towards the osteoblast lineage.
TGF-β1 prolongs BMP-2 signaling and reduces the expression of
the BMP-2 antagonist, noggin
To gain insight into the mechanism determining the stimulatory
effect of TGF-β1 on the BMP-2-triggered osteoblast differentiation,
we stimulated ST2 cells with TGF-β1 and/or BMP-2 and
monitored the levels of phosphorylated Smad1/5/8 and Smad2
proteins (Fig. 5a–c). BMP-2 stimulation resulted in increased active
Fig. 1 Release of TGF-β1 and BMP-2 proteins from the cortical bone and the induction of Smad signaling in mesenchymal stromal ST2 cells. a,
b ELISA quantiﬁcation of TGF-β1 (a) and BMP-2 (b) proteins contained in bone-conditioned medium extracted from the cortical bone chips
with either Ringer’s solution (BCM-RS) or Ringer’s solution mixed with autologous serum (BCM-RS+S) at a 1:1 ratio. The two types of media
were collected at 10, 20, and 40min, as well as at 1, 3, and 6 d. Controls (ctrl) represent RS or RS+S, not containing bone particles (controls
exhibited no detectable levels of the two proteins tested). Mean±standard deviations represent three independent BCM preparations, and
signiﬁcant differences to the respective controls (***P < 0.001, **P < 0.01, ns non-signiﬁcant) are shown. c, d BCM induces enhanced
phosphorylation of TGF-β1- and BMP-2-speciﬁc R-Smads in mesenchymal stromal ST2 cells. Immunoblot analyses of phospho-Smad2
(pSmad2) (c) and phospho-Smad1/5/8 (pSmad1/5/8) (d) proteins in whole-cell extracts from ST2 cells treated with BCM-RS or BCM-RS+S used
in a, b. The bar charts represent densitometric quantiﬁcation of the immunoblots. pSmad2 and pSmad1/5/8 levels are normalized to vinculin
loading controls. Data represent mean±SD obtained from three independent experiments. Signiﬁcant differences to the control cells treated
with RS or RS+S (**P < 0.01, *P < 0.05) are shown
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Smad1/5/8 levels after 24 h, which were reduced on day 2 after
the treatment (Fig. 5a, b). However, when the cells were co-
stimulated with both growth factors, the pSmad1/5/8 levels
remained high on day 2, suggesting that TGF-β1 prolongs
BMP2 signaling. In contrast, Smad2 phosphorylation was
enhanced upon stimulation with TGF-β1 on day 1 but was
signiﬁcantly reduced on day 2, irrespective of the presence or
absence of exogenous BMP-2 during the stimulation (Fig. 5a, c).
It is well known that in response to BMP-2, 4, or 6, osteoblasts
dramatically upregulate the expression of the secreted glycopro-
tein noggin, which in turn can limit excessive exposure of cells to
BMP signaling through a negative feedback loop.21 This prompted
us to investigate the effect of TGF-β1 on BMP-2-induced noggin
expression in ST2 cells (Fig. 5d). When the two growth factors
were applied concomitantly, TGF-β1 signiﬁcantly reduced the
BMP-2-induced Nog mRNA levels in a dose-dependent manner.
This might enable prolonged BMP signaling, ultimately contribut-
ing to increased osteoblast differentiation.
DISCUSSION
GBR with a combination of autologous bone chips, DBBM
particles, and collagen membranes has consistently shown
favorable regenerative outcomes with accelerated bone formation
and long-term peri-implant hard and soft tissue stability.2,7,22,23
During the augmentation procedure, the surgeon has the viable
option to harvest the autologous bone chips locally and store
them in a dish containing physiological solution and the patient’s
own blood during the time of the surgical implant site
preparation, lasting on average for 45min. Such short-term-
extracted BCM can be further used to pre-coat the biomaterials
used in the GBR procedure. Thus, the aim of the present study is to
extract BCM for the time periods and conditions that are typically
encountered in everyday clinical practice and to investigate its
activity on the proliferative and osteogenic potential of mesench-
ymal stromal ST2 cells.
Our data demonstrated a rapid release of TGF-β1 from
autologous bone chips within 10 min versus a delayed BMP-2
release from 40min onwards, suggesting that TGF-β1 and BMP-2
may act both simultaneously and in a sequential manner to
promote ST2 cell differentiation towards the osteoblast pheno-
type. Indeed, we showed that BCMs extracted within short time
periods (10, 20, and 40min), corresponding to the time of a typical
surgical procedure, act by increasing ST2 cell proliferation and by
inducing Col1 and Spp1 gene expression. These ﬁndings agree
with in vivo ﬁndings, showing that the exogenous delivery of TGF-
β enhances bone regeneration around orthopedic implants over a
4-week period with increased regenerated bone volume fraction,
bone contact area, and reduced implant-tissue gap,24 likely
because of the ability of TGF-β to induce the proliferation and
recruitment of osteoprogenitors to the implant site. However,
depending on the context, inhibitory effects of TGF-β on bone
formation have also been reported, e.g., transgenic mice with an
osteoblast-speciﬁc overexpression of TGF-β2 exhibited an
osteoporosis-like phenotype,25 whereas, the pharmacological
blocking of TGF-β signaling yielded increased bone formation in
mature mice.26 In our study, we found that BCMs extracted within
longer time periods (1, 3, and 6 days), corresponding to the early
days after the augmentation procedure, act by promoting the
later stages of osteoblast differentiation including matrix miner-
alization. In contrast, short-term-extracted BCMs, in which TGF-β1
but no BMP-2 was detected, caused a decrease in the expression
of the late differentiation markers Bglap2 and Ibsp. As soon as
both growth factors were simultaneously present in the BCM, no
inhibitory effects on osteoblast differentiation were evident,
suggesting a synergistic interplay between TGF-β1 and BMP-2.
Consequently, we showed a stimulatory and dose-dependent
effect of recombinant TGF-β1 on BMP-2-induced osteoblast
differentiation. Thus, besides the well-acknowledged inhibitory
effects of TGF-β on the later phases of osteoblast differentiation
and maturation,27–29 as well as the reported opposite effects of
TGF-β and BMP on osteoblast differentiation,30,31 our study
indicates that TGF-β1 alone as well as in conjunction with BMP-
2 can certainly exert positive effects on the osteogenic process.
Consistent with our ﬁndings, others have shown that TGF-β can
enhance BMP-7-induced in vivo bone formation in primates.32
Furthermore, it was shown that blocking TGF-β signaling, by
means of siRNA-mediated knockdown of its receptors or
pharmacological inhibition of ALK5 kinase activity, impedes
BMP-6-induced osteoblast differentiation.33
Our study further aimed to discover the mechanism by which
TGF-β1 exerts its stimulatory effect on the BMP-2-triggered
osteoblast differentiation. We found that upon co-stimulation
with TGF-β1 and BMP-2, phosphorylated Smad1/5/8 levels in ST2
cells were maintained for a longer period of time, suggesting that
TGF-β1 enables prolonged BMP signaling, and thus contributes to
the increased osteoblast differentiation. Moreover, we offer a
possible explanation for the prolonged BMP signaling through our
ﬁnding that TGF-β1 signiﬁcantly inhibited BMP-2-induced noggin
transcription. Other signaling molecules such as Sox9, TGF-β3,
Fig. 2 BCM extracted for short time periods induces proliferation of ST2 cells. Proliferation rates of ST2 cells treated with BCM-RS or BCM-RS
+S, which were extracted for different time periods as described in Fig. 1a, b, were assessed by BrdU incorporation into newly synthesized
DNA immediately after plating (0 h), as well as at 24, 48, 72, and 96 h. Experimental values were normalized to the values of control (ctrl) cells
treated with RS or RS+S at time point 0. Mean± standard deviations represent four independent experiments, and signiﬁcant differences to
the control cells (***P < 0.001, **P < 0.01, *P < 0.05) are shown
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Fig. 3 BCM induces osteoblast differentiation of ST2 cells. a–g Effect of BCM-RS or BCM-RS+S extracted for different time periods, as
described in Fig. 1a, b, on Col1a1 (a), Col1a2 (b), Spp1 (c), Runx2 (d), Bglap2 (e), Ibsp (f), and Alpl (g) mRNA levels. ST2 cells were treated with
20% BCM-containing osteogenic media for 24 h before total RNA was extracted and analyzed by qRT-PCR. Values normalized to Gapdh are
expressed relative to the values of control (ctrl) cells treated with 20% RS- or RS+S-containing osteogenic media. Data represent mean±SD
obtained from three independent experiments. Signiﬁcant differences to the respective control (***P < 0.001, **P < 0.01, *P < 0.05) are shown.
h, i Effect of the BCM-RS preparations on the mineral deposition capacity of ST2 cells. Cells were treated with 20% BCM-containing osteogenic
media for 14 days before extracellular matrix mineralization was analyzed by alizarin red staining. Cells cultured under the same conditions in
20% RS-containing osteogenic media were used as controls (ctrl). Mineral deposition was assessed and quantiﬁed by measuring the stained
area using the Fiji distribution of ImageJ (h). Values normalized to DNA content are expressed relative to the values of control cells. Data
represent mean± standard deviations obtained from three independent experiments. Signiﬁcant differences to the control (***P < 0.001) are
shown. Representative images of the staining in each of the experimental groups are shown (i). Scale bar=500 µm
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FGF-2, and -18 are shown to regulate BMP signaling by
manipulating noggin expression.33–36 By suppressing noggin,
endogenously produced BMP agonists may be left unopposed
to drive the differentiation of osteoprogenitors, thereby leading to
more rapid bone formation and bone defect repair. Given that
BCM is enriched in numerous growth factors, we hypothesized
that the suppression of noggin by the interplay between
simultaneously present growth factors might promote BCM-
induced BMP signaling and subsequent osteogenesis.
A clear limitation of the present study is the use of porcine
mandibular cortical bone for the preparation of the BCM. Future
research is needed to investigate the time-dependent release of
growth factors in BCM harvested from autologous bone chips of
human origin. Moreover, mass spectrometry-based strategies
should be utilized to qualitatively and quantitatively probe human
BCM on a proteome scale. Another limitation of the study is the
use of a single surgical technique (a bone scraper) to obtain the
bone chips needed for the preparation of BCM. BCM harvested
from the bone chips obtained using a bone mill, piezo-surgery, or
bone drill might have a different composition, and different
quantities of paracrine growth factors might be released over
time.
Despite the clear limitations that need to be addressed by
future research, our data represent a conceptual advance in the
understanding of the favorable outcome achieved with the use of
BCM and autografts in implant dentistry and point to a novel
Fig. 4 TGF-β1 exhibits a stimulatory and dose-dependent effect on BMP-2-induced osteoblast differentiation. a, b Effect of recombinant TGF-β1
and BMP-2 on the expression of osteoblast-speciﬁc genes in ST2 cells. Cells were treated with increasing concentrations (0.0, 0.5, 2.5, and 5.0
ng·mL-1) of TGF-β1 in the absence (−) or presence (+) of 100 ng·mL-1 BMP-2 for 24 h before total RNA was extracted. Expression of Col1a1,
Col1a2, and Spp1 mRNAs (a), as well as Runx2, Bglap2, Ibsp, and Alpl mRNAs (b) was analyzed by qRT-PCR. Values normalized to Gapdh are
expressed relative to the values of untreated cells. Mean± standard deviations were obtained from three independent experiments, and
signiﬁcant differences to either untreated cells or cells treated with BMP-2 alone (***P < 0.001, **P < 0.01, *P < 0.05) are shown. c Effect of the
recombinant TGF-β1 and BMP-2 on the mineral deposition capacity of ST2 cells. Cells were treated with TGF-β1 (5 ng·mL-1), BMP-2 (100 ng·mL-1),
or both growth factors for 4 d, and were subsequently grown under osteogenic culture conditions for 10 additional days before extracellular
matrix mineralization was assessed by alizarin red staining. Representative images are shown. Scale bar=500 µm. Mineral deposition capacity
was quantiﬁed by measuring the stained area using the Fiji distribution of ImageJ. Values normalized to the DNA content are expressed relative
to the values of untreated control cells (ctrl). Data and statistical signiﬁcance are expressed as in a, b
BCM exhibits synergistic TGF-β1/BMP-2 activity
M.B. Asparuhova et al.
6
International Journal of Oral Science (2018) 10:72 – 80
synergistic relationship between the TGF-β1 and BMP-2 growth
factors contained in BCM for the stimulation of osteogenic
differentiation. Our ultimate objective is to translate the basic
scientiﬁc observations into clinical practice. The current study
provides strategies towards achieving this goal. First, the mixture
of patient blood and RS, in which the autologous bone chips are
placed and stored for a minimum of 20min during surgical
implant site preparation, might induce downstream signaling
events upon transplantation. Second, BCM obtained during the
time of the surgical procedure as well as BCM released from the
autograft in situ within 1 day after the augmentation procedure
might expand the pool of committed osteoblasts by inducing cell
proliferation. Finally, BCM extracted within the time of the surgical
procedure has sufﬁcient potency to stimulate the production of
bone matrix, whereas BCM released from the autograft in situ after
the surgical procedure will continuously contribute to the
progression of osteogenesis.
MATERIALS AND METHODS
BCM preparation and ELISA protein quantiﬁcation
BCM was prepared as described.12 In brief, cortical bone chips
were harvested from the buccal side of fresh pig mandibles
(slaughterhouse: Küng Metzgerei, Toffen, Switzerland) using a
bone scraper (Hu-Friedy, Rotterdam, The Netherlands) and were
placed into either Ringer’s solution (RS) or Ringer’s solution
mixed with autologous serum (RS+S) at a 1:1 ratio. A ratio of 5 g
bone chips per 10 mL medium was used. Each of the two
types of media, abbreviated as BCM-RS and BCM-RS+S, was
supplemented with antibiotics and antimycotics. BCM from
four independent preparations was collected at 10, 20, and
40 min and at 1, 3, and 6 days, sterile-ﬁltered, and kept frozen at
−80 °C.
The release of TGF-β1 or BMP-2 protein in BCM preparations
was quantiﬁed using Quantikine® colorimetric sandwich ELISA
(R&D Systems, Zug, Switzerland), according to the manufacturer’s
procedure. Absorbance was measured at 450 and 570 nm using an
ELx808 Absorbance Reader (BioTek, Luzern, Switzerland). Data
represent mean±SD from three independent experiments per-
formed in duplicate.
Cell culture and proliferation assay
ST2 mesenchymal stromal cells isolated from mouse bone marrow
were obtained from RIKEN Cell Bank (Tsukuba, Japan), and were
grown in DMEM medium supplemented with 10% fetal calf serum
(FCS; Invitrogen, Zug, Switzerland). For the differentiation
Fig. 5 TGF-β1 prolongs BMP-2 signaling and reduces the expression of the BMP-2 antagonist noggin. a Immunoblots of phospho-Smad1/5/8
(pSmad1/5/8) and phospho-Smad2 (pSmad2) proteins in whole-cell extracts of ST2 cells that were either untreated or treated with
recombinant TGF-β1 (5 ng·ml−1), BMP-2 (100 ng·mL-1) or both growth factors. Cell lysates were collected on two consecutive days after the
treatment. Anti-vinculin served as a loading control. b, c Densitometric analyses of the immunoblots shown in a. pSmad1/5/8 (b) and pSmad2
(c) protein levels are normalized to the vinculin loading controls. Mean± standard deviations were obtained from three independent
experiments, and signiﬁcant differences to either untreated cells or between identically treated cells on day 1 and 2 after the stimulation (***P
< 0.001, **P < 0.01) are shown. d Effect of TGF-β1 on BMP-2-induced noggin expression in ST2 cells. Cells were treated with increasing
concentrations (0.0, 0.5, 2.5, and 5.0 ng·mL-1) of TGF-β1 in the absence (−) or presence (+) of 100 ng·mL-1 BMP-2 for 24 h before total RNA was
extractedand Nog mRNA levels were analyzed by qRT-PCR. Values normalized to Gapdh are expressed relative to the values of untreated cells.
Mean± standard deviations were obtained from three independent experiments, and signiﬁcant differences to either untreated cells or cells
treated with BMP-2 alone (***P < 0.001) are shown
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experiments, media were supplemented with 50 ascorbic acid
(Invitrogen) and 2mM β-glycerophosphate (Invitrogen), as
described.9 Cells were treated with either ﬁvefold-diluted BCM or
recombinant TGF-β1 and/or BMP-2 proteins (PeproTech, London,
UK) for 30min (protein analyses), 24 h (RNA analyses), or 4 days
(mineralization analyses).
Proliferation rates of BCM-treated ST2 cells were determined
using a BrdU incorporation assay (Roche, Basel, Switzerland), as
described.37 In brief, after 24 h of starvation, the cells were plated
in triplicate on black 96-well plates (PerkinElmer, Basel, Switzer-
land) at 2 × 103 cells/well in 3% FCS/DMEM and were allowed to
proliferate for 0, 24, 48, 72, and 96 h before labeling with BrdU for
2 h. BrdU incorporation into newly synthesized DNA was
determined according to the manufacturer’s protocol using an
Inﬁnite® 200 luminometer (Tecan, Männedorf, Switzerland).
Experimental values were normalized to the values of ST2 cells
treated with RS or RS+S at time point 0. Data represent means±SD
from four independent experiments.
qRT-PCR
Total RNA from BCM- or growth factor-treated ST2 cells was
isolated using the RNeasy Mini Kit (Qiagen, Basel, Switzerland).
RNA was reverse transcribed, and relative transcript levels for
Col1a1, Col1a2, Spp1, Runx2, Bglap2, Ibsp, Alpl, and Nog genes,
normalized to Gapdh, were measured using FastStart Universal
SYBR Green Master ROX (Roche) and the primer sequences
listed in Table 1. qPCR was carried out in a 7500 Real-Time PCR
System (Applied Biosystems, Rotkreuz, Switzerland) using a
standard thermal cycling proﬁle. Data were analyzed using
the efﬁcient ΔΔCt method.38 All samples were run in
duplicate. Data represent means±SD from three independent
experiments.
Immunoblotting
Whole-cell extracts from BCM- or growth factor-treated ST2 cells
were prepared by lysis in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150
mmol·L-1 NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mmol·L-1
EDTA, 1 × complete Protease Inhibitor Cocktail (Roche)), as
described.39 Samples were run on 10% SDS–PAGE and transferred
to Protran® membranes (Sigma, Buchs, Switzerland). Proteins of
interest were visualized using anti-phospho-Smad1/5/8 (Cell
Signaling Technology, Leiden, The Netherlands), anti-phospho-
Smad2 (ThermoFisher Scientiﬁc, Reinach, Switzerland), and
anti-vinculin (Sigma) antibodies, followed by horseradish
peroxidase-conjugated secondary antibodies for detection with
the SuperSignal™ West Dura Substrate (ThermoFisher Scientiﬁc).
Phospho-Smad1/5/8 or phospho-Smad2 protein expression, rela-
tive to the vinculin loading control, was quantiﬁed by densito-
metry using ImageQuant Software (Molecular Dynamics Inc.,
Sunnyvale, CA, USA). Data represent mean±SD from three
independent experiments.
Alizarin red staining
Mineral deposition of BCM- or growth factor-treated ST2 cells was
analyzed by alizarin red staining after 14 days using 0.2% Alizarin
Red S (Sigma), pH 6.4. Images were acquired on an Olympus
BX-51. Mineralization was quantiﬁed by measuring the stained
area using the Fiji distribution of ImageJ.40 Cellular DNA content,
as measured by the CyQUANT® NF assay (Invitrogen), was used for
normalization. Data represent mean±SD from three independent
experiments.
Statistical analysis
All grouped data are mean±SD. Differences between the groups
were assessed by one-way analysis of variance (ANOVA) using
GraphPad InStat Software, version 3.05. Values of P < 0.05 were
considered signiﬁcant.
Data availability statement
Availability of data and materials should be included here.
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Table 1. Primer sequences
Gene symbol Gene bank accession number Primer pair (fwd/rev) Amplicon size (bp)
Col1a1 NM_007742.3 5′- CCGGAAGAATACGTATCACCA-3′
5′- TCTGGGAAGCAAAGTTTCCT-3′
199
Col1a2 NM_007743.3 5′- CTTACTGGGAACTTTGCTGCTC-3′
5′- TTTCCAGGGTGACCATCCTC-3′
229
Spp1 NM_001204201.1 5′- GGAAACCAGCCAAGGTAAGC-3′
5′- TGCCAATCTCATGGTCGTAG-3′
92
Runx2 NM_001271627.1 5′- AGGGACTATGGCGTCAAACA-3′
5′- GGCTCACGTCGCTCATCTT-3′
137
Bglap2 NM_001032298.3 5′- CACCTAGCAGACACCATGAG-3′
5′- TGGACATGAAGGCTTTGTCAG-3′
123
Ibsp NM_008318.3 5′- GGTCTTTAAGTACCGGCCAC-3′
5′- CGTTTGAAGTCTCCTCTTCCTC-3′
157
Alpl NM_001287172.1 5′- GCAACTCCATCTTTGGTCTG-3′
5′- GTTGTTGTGAGCGTAATCTACC-3′
145
Nog NM_008711.2 5′- GCCAGCACTATCTACACATCC-3′
5′- GCGTCTCGTTCAGATCCTTCTC-3′
114
Gapdh NM_008084.2 5′-CTTGTGCAGTGCCAGCCTC-3′
5′-GCCGTGAGTGGAGTCATACTG-3′
189
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